Literature DB >> 11898537

Parkinson's disease: the treatment of drug-induced hallucinations and psychosis.

E S Molho1, S A Factor.   

Abstract

Drug-induced psychosis is one of the most disabling complications of advancing Parkinson's disease. It has also been one of the most difficult to treat. Clozapine was the first medication shown to be safe and effective in this setting, and it remains the standard by which newer atypical antipsychotics are measured. However, due to the small but significant risk of agranulocytosis and the need for frequent blood testing, alternatives have been sought. Risperidone, olanzapine, and quetiapine are new atypical antipsychotics that have each been proposed as an alternative to clozapine, but the literature concerning their use in Parkinson's disease is conflicted and confusing. Although quetiapine appears to be the best current choice, none of these medications have equaled clozapine's ability to safely treat drug-induced psychosis without the risk of worsening parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898537     DOI: 10.1007/s11910-001-0085-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  43 in total

Review 1.  The emerging role of clozapine in the treatment of movement disorders.

Authors:  S A Factor; J H Friedman
Journal:  Mov Disord       Date:  1997-07       Impact factor: 10.338

Review 2.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

3.  Olanzapine can worsen parkinsonism.

Authors:  F J Jiménez-Jiménez; A Tallón-Barranco; M Ortí-Pareja; M Zurdo; J Porta; J A Molina
Journal:  Neurology       Date:  1998-04       Impact factor: 9.910

4.  Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.

Authors:  E Mohr; T Mendis; K Hildebrand; P P De Deyn
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

Review 5.  'Drug holidays' in the treatment of Parkinson's disease. A brief review.

Authors:  J H Friedman
Journal:  Arch Intern Med       Date:  1985-05

6.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

Authors:  D Aarsland; J P Larsen; J L Cummins; K Laake
Journal:  Arch Neurol       Date:  1999-05

7.  Risperidone treatment of drug-related psychosis in patients with parkinsonism.

Authors:  N A Leopold
Journal:  Mov Disord       Date:  2000-03       Impact factor: 10.338

8.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

9.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease.

Authors:  C G Goetz; G T Stebbins
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

10.  Acute postoperative confusion and hallucinations in Parkinson disease.

Authors:  W E Golden; R C Lavender; W S Metzer
Journal:  Ann Intern Med       Date:  1989-08-01       Impact factor: 25.391

View more
  3 in total

1.  Visual Hallucinations.

Authors:  Victoria S. Pelak; Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

2.  A clinical profile of patients with Parkinson's disease and psychosis.

Authors:  B R Amar; Ravi Yadav; Y C Janardhan Reddy; Pramod Kumar Pal
Journal:  Ann Indian Acad Neurol       Date:  2014-04       Impact factor: 1.383

3.  What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study.

Authors:  Nakyung Jeon; Marco Bortolato
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.